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Abstract Aspirin and other non-steroidal anti-inflammatory
drugs induce apoptosis in many cell types. Although the
involvement of caspases has been demonstrated, the mechanism
leading to caspase activation remains unknown. We have studied
the role of the mitochondrial pathway in aspirin-induced
apoptosis. The apoptotic effect of aspirin was analyzed in
different cell lines (Jurkat, MOLT-4, Raji and HL-60) showing
induction of mitochondrial cytochrome c release and caspases 9,
3 and 8 processing. Furthermore, early aspirin-induced cyto-
chrome c release was not affected by the caspase inhibitor Z-
VADWfmk and preceded loss of mitochondrial membrane
potential. Therefore, aspirin-induced apoptosis involves caspase
activation through cytochrome c release. ß 2000 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
Aspirin and other non-steroidal anti-in£ammatory drugs
(NSAIDs) induce apoptosis in several cell types, including
human colorectal tumor cell lines [1^4], ¢broblasts [5,6], B-
cell chronic lymphocytic leukemia cells [7] and myeloid leuke-
mia cell lines [8]. Furthermore, administration of NSAIDs
induces apoptosis of colon cancer cells in vivo [9,10].
The apoptotic action of NSAIDs was inhibited by the cas-
pase inhibitor Z-VADWfmk, demonstrating the involvement of
caspases [4,7,8]. However, the pathway leading to caspase
activation remains unknown. Caspases play a central role in
the execution of programmed cell death [11]. The two most
well-studied pathways of caspase activation include the sur-
face death receptor pathway and the mitochondrion-initiated
pathway [12]. In the mitochondrial pathway, cytochrome c
and other apoptogenic proteins (e.g. apoptosis-inducing factor
[13]) are released from the intermembrane space to the cytosol
[14,15]. Once released, cytochrome c binds to Apaf-1 and in-
duces activation of caspase 9 [16].
In the present study, we examined the role of the mitochon-
drial pathway in aspirin-induced apoptosis. In particular, the
relationship between cytochrome c release, caspase activity
and loss of mitochondrial membrane potential (v8m) was
analyzed. Our results indicate that aspirin triggers cytochrome
c release as an early event preceding caspase activation and
loss of v8m.
2. Materials and methods
2.1. Cell culture
The human cell lines Jurkat and MOLT-4 (acute T leukemia), Raji
(B-cell Burkitt lymphoma) and HL60 (promyelocytic leukemia) were
from the European Collection of Cell Cultures. Cells were grown in
RPMI 1640 medium (Biological Industries, Beit Haemek, Israel) con-
taining 10% heat-inactivated fetal bovine serum (FBS) (Gibco-BRL,
Paisley, UK), 2 mM L-glutamine, 100 U/ml penicillin and 100 Wg/ml
streptomycin at 37‡C in a humidi¢ed atmosphere at 5% carbon diox-
ide.
2.2. Reagents
Aspirin (acetylsalicylic acid) and propidium iodide (PI) were from
Sigma Chemicals Co. (St Louis, MO, USA). Annexin V-FITC was
from Bender MedSystems (Vienna, Austria). Z-VADWfmk (benzyloxy-
carbonyl-Val-Ala-Asp-£uoromethyl ketone) was from Bachem AG
(Bubendorf, Switzerland). JC-1 was from Molecular Probes Europe
BV (Leiden, The Netherlands).
2.3. Analysis of viability by phosphatidylserine exposure and PI uptake
Cell viability was determined by analyzing phosphatidylserine ex-
posure and membrane integrity by double staining with annexin V-
FITC and PI, prior to £ow cytometric analysis (FACSCalibur, Becton
Dickinson, Mountain View, CA, USA), as previously described [4].
Data analysis was performed with CellQuest software (Becton Dick-
inson). Cell viability was measured as the percentage of annexin V-
and PI-negative cell population.
2.4. Western blot analysis of caspases
Whole cell protein extracts were obtained by lysing cells with
Laemmli sample bu¡er [17]. Protein concentration was measured
with the Micro BCA Protein Assay Reagent kit (Pierce, Rockford,
IL, USA). For Western blot, protein extracts (50 Wg) were subjected
to reduction conditions before being subjected to electrophoresis on a
12% polyacrylamide gel and then transferred to Immobilon-P mem-
branes (Millipore, Bedford, MA, USA). Membranes were incubated
with the polyclonal antibody against cleaved caspase 9 (New England
Biolabs) or monoclonal antibodies against caspase 3 (Transduction
Laboratories, Lexington, KY, USA) or caspase 8 (Cell Diagnostica,
Mu«nster, Germany). Antibody binding was detected with a horserad-
ish peroxidase-coupled anti-mouse or anti-rabbit secondary antibody
(Amersham, Bucks, UK) and the enhanced chemiluminescence (ECL)
detection kit (Amersham).
2.5. Cytochrome c release measurements
Release of cytochrome c from mitochondria to cytosol was mea-
sured by Western blot as previously described [18] with some modi¢-
cations. Cells (5U106) were harvested, washed once with ice-cold
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phosphate-bu¡ered saline and gently lysed for 30 s in 80 Wl ice-cold
lysis bu¡er (250 mM sucrose, 1 mM EDTA, 0.05% digitonin, 25 mM
Tris, pH 6.8, 1 mM dithiothreitol, 1 Wg/ml leupeptin, 1 Wg/ml pepsta-
tin, 1 Wg/ml aprotinin, 1 mM benzamidine, and 0.1 mM phenylmeth-
ylsulfonyl £uoride). Lysates were centrifuged at 12 000Ug at 4‡C for
3 min to obtain the supernatants (cytosolic extracts free of mitochon-
dria) and the pellets (fraction that contains mitochondria). Superna-
tants (50 Wg) and pellets (40 Wg) were electrophoresed on a 15% poly-
acrylamide gel and then analyzed by Western blot using anti-
cytochrome c antibody (7H8.2C12, from Pharmingen, San Diego,
CA, USA) and cytochrome oxidase subunit II antibody (Molecular
Probes) and ECL, as described above.
2.6. Analysis of changes in v8m
Changes in v8m were determined by staining the cells with JC-1
(Molecular Probes) prior to £ow cytometry analysis (FACSCalibur,
Becton Dickinson), as previously described [19]. Data analysis was
performed with CellQuest software (Becton Dickinson) by measuring
both the green (530 þ 15 nm, FL-1) and red (585 þ 21 nm, FL-2) JC-1
£uorescence. The loss in v8m is seen as a shift to lower JC-1 red
£uorescence accompanied by an increase in JC-1 green £uorescence.
At least 10 000 events were collected per sample.
3. Results
3.1. Aspirin induces mitochondrial cytochrome c release and
caspase 9, 3 and 8 processing
In order to study the mechanism of aspirin-induced apopto-
sis we ¢rst tested its e¡ect on di¡erent cell lines. Jurkat,
MOLT-4, Raji and HL-60 cells were incubated with 10 mM
aspirin for 12 h and cell viability was quanti¢ed as the per-
centage of annexin V- and PI-negative cells. As shown in Fig.
1A, aspirin induced about 50^60% decrease in cell viability in
all cell lines tested. Furthermore, an increase in the percentage
of cells with low DNA content was also detected (data not
shown). To analyze the involvement of cytochrome c release
in aspirin-induced apoptosis, cytosolic and mitochondrial
fractions were obtained and analyzed for the presence of cy-
tochrome c by Western blot. As shown in Fig. 1B, aspirin
induced the appearance of cytochrome c in the cytosolic frac-
tions of Jurkat and Raji treated cells and its disappearance
from the mitochondrial fraction of the four treated cell lines,
indicating that aspirin induced mitochondrial cytochrome c
release. As a control for mitochondrial protein loading, cyto-
chrome oxidase subunit II was also analyzed in the mitochon-
drial fraction by Western blot.
Cytosolic cytochrome c binds to Apaf-1 and induces acti-
vation of caspase 9 [16]. To demonstrate that this pathway
was activated in aspirin-induced apoptosis, caspase 9 was an-
alyzed by Western blot in whole cell extracts. Aspirin induced
processing of caspase 9 in the four cell lines, as shown by the
appearance of caspase 9 intermediate cleavage product (37
kDa) and the disappearance of the precursor form. Caspases
3 and 8 have been described to be activated downstream of
caspase 9 [20]. Aspirin induced processing of caspases 3 and 8,
as shown by the appearance of the caspase 8 intermediate
cleavage product (43/41 kDa) and the disappearance of the
precursor forms of caspases 3 and 8 in the four cell lines (Fig.
1C).
3.2. Aspirin-induced cytochrome c release precedes caspase
activation and loss of v8m
Cytochrome c release can be dependent on or independent
of caspase activity [12]. Thus, we analyzed the time kinetics of
cytochrome c release and its dependence on caspase activity in
Jurkat cells. Cells were treated with 10 mM aspirin in the
presence or absence of the caspase inhibitor Z-VADWfmk
(100 WM) for the indicated times and cytosolic extracts and
whole cell extracts were obtained for cytochrome c release and
caspase processing analysis, respectively. As shown in Fig. 2A,
aspirin induced cytochrome c release in a time-dependent
manner. Cytosolic cytochrome c levels were slightly increased
as early as 3 h and markedly increased at 4 h. Aspirin-induced
cytochrome c release was not modi¢ed by the presence of Z-
VADWfmk until 6 h. At longer times, Z-VADWfmk partially
inhibited the accumulation of cytochrome c in the cytosol.
These results demonstrate that aspirin induces cytochrome c
release in two stages, corresponding to an early cytochrome c
release independent of caspase activity and a late cytochrome
c release dependent on caspase activity. As shown in Fig. 2A,
aspirin induced processing of caspase 9 at 3 h, simultaneous to
cytochrome c release. Cell viability decreased markedly at
6 and 12 h. The presence of Z-VADWfmk inhibited both the
Fig. 1. E¡ect of aspirin on cell viability, cytochrome c release and
caspase processing. Jurkat, MOLT-4, Raji and HL-60 cell lines were
treated with 10 mM aspirin (ASA) for 12 h. A: Analysis of cell via-
bility by phosphatidylserine exposure and PI uptake. Cell viability
was measured as the percentage of annexin V- and PI-negative cell
population. B: Analysis of cytochrome c in cytosolic (CYT) and mi-
tochondrial (MIT) extracts, by Western blot. Cytochrome oxidase
subunit II (Cyt ox.) was also analyzed in the mitochondrial extracts,
as a control for mitochondrial protein loading. C: Analysis of the
processing of caspases 9, 3 and 8. Whole cell extracts were analyzed
by Western blot with antibodies against caspases 9, 3 and 8. The
migration position of precursor forms and the cleavage products
caspase 9 (37 kDa) and caspase 8 (43/41 kDa) are indicated.
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processing of caspase 9 and the decrease in cell viability at all
times analyzed.
It has been described that cytochrome c release can be
induced by mitochondrial permeability transition (PT) char-
acterized by loss of v8m [15,21,22]. As salicylates induce mi-
tochondrial PT and loss of v8m in isolated mitochondria
[23,24] and hepatocytes [25], we analyzed the e¡ect of aspirin
on v8m in Jurkat cells using the JC-1 dye. As shown in Fig.
2B, aspirin had no e¡ect on v8m at 4 h and induced loss of
v8m at 6 and 12 h, later than mitochondrial cytochrome c
release and caspase 9 processing. Furthermore, Z-VADWfmk
blocked loss of v8m induced by aspirin at 6 h and had a
marked inhibitory e¡ect at 12 h, indicating that loss of v8m
is caspase-dependent. Altogether, these results demonstrate
that aspirin-induced cytochrome c release precedes loss of
v8m.
4. Discussion
The mechanism underlying the induction of apoptosis by
aspirin, salicylate and other NSAIDs is unknown and cur-
rently under research. So far, several pathways have been
implicated including cyclooxygenase inhibition [26,27], p38
mitogen-activated protein kinase activation [6], nuclear fac-
tor-UB inhibition [28,29], and peroxisome proliferator-acti-
vated receptor N inhibition [30]. Although several groups
have demonstrated the involvement of caspases [4,7,8,31],
the pathways leading to caspase activation remain unknown.
The results reported in this paper show that aspirin induces
caspase activation through cytochrome c release from mito-
chondria preceding loss of v8m.
Release of cytochrome c from mitochondria is a central
event in apoptosis [32,33]. Our results demonstrate that cyto-
chrome c release from mitochondria is an early event in aspir-
in-induced apoptosis. The fact that early aspirin-induced cy-
tochrome c release is not inhibited by Z-VADWfmk
demonstrates that this event is caspase-independent. Once cy-
tochrome c is released, a sequential ordering of caspase acti-
vation has been reported [20]. Our results demonstrate that
aspirin induces activation of caspases 9, 3, and 8. Thus, the
early aspirin-induced cytochrome c release could be su⁄cient
to trigger caspase activation.
Salicylates induce mitochondrial PT and loss of v8m in
isolated mitochondria [23,24] and hepatocytes [25]. However,
our results indicate that aspirin-induced cytochrome c release
precedes the decrease in v8m in intact cells. Furthermore,
pretreatment of Jurkat cells with Z-VADWfmk inhibited loss
of v8m whereas no e¡ect was detected on early cytochrome c
release. These facts indicate that the decrease in v8m may be
a consequence of caspase activity rather than the e¡ector
mechanism of aspirin-induced cytochrome c e¥ux. Thus,
loss of v8m is not required for aspirin-induced release of
cytochrome c and apoptosis, as described for many apoptotic
stimuli including staurosporine, hydrogen peroxide, Fas, UVB
irradiation, DNA-damaging agents and ionizing radiation
[19,34^40]. The caspase-dependent drop in the v8m and late
cytochrome c release may have a role as a potentiating mech-
anism by a feedback ampli¢cation loop linking caspase acti-
vation and mitochondrial dysfunction.
In conclusion, the results presented in this report demon-
strate that aspirin-induced apoptosis involves release of cyto-
chrome c from mitochondria preceding caspase activation and
loss of v8m. The elucidation of the mechanisms involved in
the induction of cytochrome c release by aspirin warrants
further investigation.
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